Cargando…

Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression

The anti-EGFR antibody cetuximab is used as a first-line targeted therapeutic drug in colorectal cancer. It has previously been reported that the efficacy of the EGFR antibody cetuximab is limited by the emergence of acquired drug resistance. In our previous study the transmissibility effect of exos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Zhenzhen, Wang, Ziyuan, Chai, Qiong, Li, Zan, Zhang, Mengjie, Zhang, Yuli, Zhang, Lu, Tang, Qingfeng, Zhu, Huirong, Sui, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852420/ https://www.ncbi.nlm.nih.gov/pubmed/36741914 http://dx.doi.org/10.3892/etm.2023.11785

Ejemplares similares

Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
por: Zhang, S., et al.
Publicado: (2017)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC
por: Yuan, Yitao, et al.
Publicado: (2023)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
por: Guo, Sheng, et al.
Publicado: (2016)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Exosomal lncRNA HCG18 contributes to cholangiocarcinoma growth and metastasis through mediating miR-424-5p/SOX9 axis through PI3K/AKT pathway
por: Ni, Qingfeng, et al.
Publicado: (2023)

Decursinol Angelate Inhibits Glutamate Dehydrogenase 1 Activity and Induces Intrinsic Apoptosis in MDR-CRC Cells
por: Chang, Sukkum Ngullie, et al.
Publicado: (2023)

Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis
por: Zhang, Yuli, et al.
Publicado: (2022)

The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC)
por: Yang, Meiqi, et al.
Publicado: (2022)

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
por: Zheng, Peng, et al.
Publicado: (2018)

Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2021)

Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis
por: Yang, Kaihua, et al.
Publicado: (2021)

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
por: Yang, Ying-nan, et al.
Publicado: (2018)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer: ACACB is a biomarker for CTX therapy in metastatic CRC
por: Hong, Hi-Ju, et al.
Publicado: (2022)

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors
por: Yang, Xin, et al.
Publicado: (2021)

CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b
por: Zhang, Qi, et al.
Publicado: (2023)

Alternate Roles of Sox Transcription Factors beyond Transcription Initiation
por: Zhang, Yuli, et al.
Publicado: (2021)

Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia
por: Arai, Makoto, et al.
Publicado: (2023)

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
por: Wang, Jinglu, et al.
Publicado: (2017)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Actinomycin V Induces Apoptosis Associated with Mitochondrial and PI3K/AKT Pathways in Human CRC Cells
por: Jiang, Shiqing, et al.
Publicado: (2021)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer
por: Yuan, Zeting, et al.
Publicado: (2020)

Silencing SOX2 Induced Mesenchymal-Epithelial Transition and Its Expression Predicts Liver and Lymph Node Metastasis of CRC Patients
por: Han, Xu, et al.
Publicado: (2012)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt
por: Cai, Ping, et al.
Publicado: (2020)

A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
por: Chen, Dawei, et al.
Publicado: (2015)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
por: Sebio, A., et al.
Publicado: (2016)

Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC
por: Bazzi, Zainab Ali, et al.
Publicado: (2023)

ARHGAP10 Inhibits the Proliferation and Metastasis of CRC Cells via Blocking the Activity of RhoA/AKT Signaling Pathway
por: Liu, Lin, et al.
Publicado: (2019)

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways
por: Liu, Shengwei, et al.
Publicado: (2017)

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
por: Kopetz, S., et al.
Publicado: (2022)

Akkermansia muciniphila inhibits tryptophan metabolism via the AhR/β-catenin signaling pathway to counter the progression of colorectal cancer
por: Zhang, Lu, et al.
Publicado: (2023)

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models
por: Dahlmann, Mathias, et al.
Publicado: (2021)

CRC handbook of microbiology
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_bt0rps72kmfd5488fv3qbhvk73